Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin and Yaz Oral Contraceptives

Barr Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Barr Laboratories, Inc. has entered into supply and licensing agreements with Bayer for generic versions of Bayer's Yasmin(R) (drospirenone and ethinyl estradiol) and Yaz(R) (drospirenone and ethinyl estradiol) oral contraceptive products. Under terms of these agreements, Bayer will supply Barr with the generic products for launch prior to the expiration of the patents protecting these products and Barr will have sole responsibility to market, sell and distribute the products in the U.S. under the Barr Laboratories label.

The details can be read here.